# BNT327-01 (NCT06449209)

> Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

No report yet. It can be ordered.

- Drugs tested: pumitamig (BNT327) plus carboplatin plus etoposide; pumitamig (BNT327) plus paclitaxel; pumitamig (BNT327) plus topotecan
- Indication: untreated extensive-stage or previously treated small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06449209
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BioNTech SE
- Conditions: Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer
- Interventions: BNT327 Dose Level 1 (DL1); BNT327 Dose Level 2 (DL2); Etoposide; Carboplatin; Paclitaxel; Topotecan
- Enrollment: 110
- Primary outcome: Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs
- Primary outcome: Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs
- Primary outcome: Objective Response Rate
- Primary outcome: Best percentage change from baseline in the tumor size
- Primary outcome: Proportion of participants who have achieved early tumor shrinkage

## Indexed commentary on BNT327-01 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bnt327-01-nct06449209
